Entest BioMedical Inc.'s Subsidiary Zander Therapeutics Files Patent Application on its Proprietary NR2F6 Target for the Treatment of Exercise Induced Pulmonary Hypertension Frequently Found in Thoroughbred Horses
Entest BioMedical Inc. (OTCPINK: ENTB) announced today that its subsidiary, Zander Therapeutics, Inc., has filed of a United States patent application covering use of newly identified activators of NR2F6 for the treatment of a Racehorse-specific condition termed "Exercise Induced Pulmonary Hemorrhage (EIPH)." This condition is characterized by the presence of blood in the airways of a horse's lung during exercise. According to a recent study, 60 percent of Thoroughbred racehorses have evidence of blood in their trachea, with 20 percent having moderate to severe EIPH (grades 2-4) after any given race. Horses with a grade 2 score or higher have significantly decreased performance.
Zander Therapeutics :: Specializing in cutting edge therapies for animals
Founded in 2015 as a biotechnology company focused on veterinary medicine, specifically small molecule treatments for veterinary cancers, autoimmune diseases such as arthritis and other immunotherapies for specialty niche treatments. Zander is a subsidiary of Entest Group Inc. a fully reporting and trades publicly under the symbol: ETNI Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing.
Copyright Zander Therapeutics, Inc. 2017